Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

This study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.

Trial Details

NCT ID
NCT06005870
Phase
PHASE2
Sponsor
Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Zanubrutinib plus RCHOP
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Age ≥18 years, ≤ 75 years, both sexes;
  • Diff use large B-cell lymphoma diagnosed by histopathology without previous systemic DLBCL treatment;
  • ECOG score: 0-2;
  • Predicted survival ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →